CSBR vs. GNTA, ENTX, CDTX, IKNA, LENZ, ALGS, TSBX, ELUT, ATRA, and AVRO
Should you be buying Champions Oncology stock or one of its competitors? The main competitors of Champions Oncology include Genenta Science (GNTA), Entera Bio (ENTX), Cidara Therapeutics (CDTX), Ikena Oncology (IKNA), LENZ Therapeutics (LENZ), Aligos Therapeutics (ALGS), Turnstone Biologics (TSBX), Elutia (ELUT), Atara Biotherapeutics (ATRA), and AVROBIO (AVRO). These companies are all part of the "biological products, except diagnostic" industry.
Genenta Science (NASDAQ:GNTA) and Champions Oncology (NASDAQ:CSBR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their community ranking, risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.
Genenta Science currently has a consensus price target of $25.00, indicating a potential upside of 706.45%. Champions Oncology has a consensus price target of $7.50, indicating a potential upside of 55.28%. Given Champions Oncology's stronger consensus rating and higher possible upside, equities research analysts plainly believe Genenta Science is more favorable than Champions Oncology.
Genenta Science has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Comparatively, Champions Oncology has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500.
Genenta Science has a net margin of 0.00% compared to Genenta Science's net margin of -19.76%. Champions Oncology's return on equity of 0.00% beat Genenta Science's return on equity.
Champions Oncology received 143 more outperform votes than Genenta Science when rated by MarketBeat users. However, 85.71% of users gave Genenta Science an outperform vote while only 60.08% of users gave Champions Oncology an outperform vote.
Champions Oncology has higher revenue and earnings than Genenta Science.
15.1% of Genenta Science shares are owned by institutional investors. Comparatively, 41.3% of Champions Oncology shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by insiders. Comparatively, 45.7% of Champions Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, Champions Oncology had 12 more articles in the media than Genenta Science. MarketBeat recorded 18 mentions for Champions Oncology and 6 mentions for Genenta Science. Genenta Science's average media sentiment score of 1.04 beat Champions Oncology's score of 0.46 indicating that Champions Oncology is being referred to more favorably in the news media.
Summary
Genenta Science beats Champions Oncology on 8 of the 15 factors compared between the two stocks.
Get Champions Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CSBR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CSBR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Champions Oncology Competitors List
Related Companies and Tools
